Investor News / RNS

The Company announces that it received notice today that Dr Jim Millen sold 597,332 ordinary shares in the Company at 6.45p per share to cover the cost of his exercise of options announced on 5 August 2020. Click here to read in full....

Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, announces that, further to its announcement earlier today and following the receipt of an additional notice of exercise of employee options, 90,000 ordinary shares of 0.4p each in the Company (“Ordinary Shares”) (the “Options Shares”) will be issued to the an employee at an exercise price...

Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, announces that following the receipt of notices of exercise of employee options, 1,655,813 ordinary shares of 0.4p each in the Company (“Ordinary Shares”) (the “Options Shares”) have now been issued to the following employees at the following exercise prices: Click here to read in full...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that, based on its unaudited management accounts for the year ended 30 June 2020, the Company is trading in line with analyst expectations. Trading for the current financial year has started well with a further contract with Bicycle Therapeutics (announced on...

Physiomics awarded contract by Astellas Pharma Inc. Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that, further to its announcements of 27 May, 30 June and 22 July 2020, it has been awarded a contract by a new client, Astellas Pharma Inc. (TSE:...

Physiomics reports that Dr Jim Millen, CEO, has transferred 85,715 ordinary shares of 0.4p each in the capital of the Company (“Ordinary Shares”), acquired during the recently placing, announced on 27 May 2020, to his account with The Share Centre for nil consideration, effective 2 July 2020.  Click here to read in full.    ...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by existing client Bicycle Therapeutics plc (Nasdaq: BCYC) (“Bicycle”).  The project involves advanced translational pharmacokinetic modelling of one of Bicycle’s pipeline assets and...

Physiomics to present on dual immuno-therapy at AACR 2020 Virtual Meeting II Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Academy of Cancer Research (“AACR”) Annual Meeting 2020, being held as a virtual event. The Company will be presenting on a new version...

TR-1: Standard form for notification of major holdings Please click here to read in full....

Physiomics completes £0.83m (gross) fundraise to fund growth opportunities Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has completed a placing and subscription, conditional on Admission, to raise approximately £828,750 (gross) from the issue of 23,678,571 new ordinary shares of 0.4p...